Clinical Trial Update: A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 randomized trial evaluated ipilimumab plus epacadostat vs ipilimumab plus placebo in unresectable or metastatic melanoma; the study was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Epacadostat (epacadostat)
• ipilimumab (ipilimumab)

Snippet

Sponsor: Incyte Corporation | Conditions: Melanoma | Phase 1, Phase 2 | Status: TERMINATED